
(low pin’ ah ver)
KaletraDNC
PREGNANCY CATEGORY C
Drug Classes
Antiviral
Protease inhibitor combination
Therapeutic Actions
Lopinavir in this combination exhibits antiviral activity; inhibits HIV protease activity, leading to the decrease in production of HIV particles; ritonavir in this preparation inhibits metabolism of lopinavir, allowing for increased plasma levels of lopinavir.
Indications
Treatment of HIV infection in combination with other antiretrovirals
Contraindications and Cautions
Contraindicated with allergy to lopinavir, ritonavir; in preterm infants.
Use cautiously with pregnancy, hepatic impairment, pancreatitis, lactation.
Available Forms
TabletsDNC—100 mg lopinavir/25 mg ritonavir, 200 mg lopinavir/50 mg ritonavir; oral solution—80 mg lopinavir/20 mg ritonavir/5 mL
Dosages
Dosage is based on lopinavir component of lopinavir/ritonavir solution (400 mg/100 mg/5 mL).
Once-daily lopinavir/ritonavir can be used in patients with less than three lopinavir-resistance-associated substitutions.
Adults and pediatric patients older than 12 yr and weighing more than 40 kg
HIV infection, with other antiretrovirals in treatment-naïve patients: 800 mg lopinavir and 200 mg ritonavir (four tablets or 10 mL) PO once daily or 400 mg lopinavir and 100 mg ritonavir PO bid with food (two tablets, or three capsules, or 5 mL)
HIV infection, with other antiretrovirals in treatment-experienced patients: 400 mg lopinavir and 100 mg ritonavir (two tablets, or three capsules, or 5 mL) PO bid.
Taken with efavirenz, nevirapine, fosamprenavir without ritonavir, or nelfinavir: 533 mg lopinavir and 133 mg ritonavir (four capsules or 6.5 mL) PO bid for treatment-experienced patients. No dosage adjustment needed for treatment-naïve patients.
Pediatric patients 6 mo to 12 yr
Dosage is usually based on weight.
Concomitant therapy with efavirenz, nevirapine, amprenavir

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

